<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336813">
  <stage>Registered</stage>
  <submitdate>14/04/2011</submitdate>
  <approvaldate>19/04/2011</approvaldate>
  <actrnumber>ACTRN12611000405910</actrnumber>
  <trial_identification>
    <studytitle>Does using progesterone in threatened miscarriage increase the live birth rate?</studytitle>
    <scientifictitle>In women with threatened miscarriage, does progesterone supplementation increase the likelihood of live birth?</scientifictitle>
    <utrn>U1111-1120-7707</utrn>
    <trialacronym>Supporting Threatened Outcomes with Progesterone 
(STOP trial)</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Threatened Miscarriage</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Progesterone pessary 400 mg nightly, until 12 weeks + 0 days</interventions>
    <comparator>Placebo pessary, identical in appearance, containing carrier compound of intervention pessary, until 12 weeks + 0 days</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Live Birth</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Complete miscarriage</outcome>
      <timepoint>Completion of index pregnacy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gestation at birth</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Birth weight</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Congenital anomaly</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Antepartum haemorrhage</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Threatened miscarriage
Live intra-uterine pregnancy
Gestation less than 10 weeks + 0 days</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy as a result of Assisted Reproductive Technologies</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Informed, meet criteria, consented, enroled, 'script' given, dispensed as blinded therapy at pharmacy according to randomisation schedule</concealment>
    <sequence>Computer-generated variable block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>30/01/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>386</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Luke McLindon</primarysponsorname>
    <primarysponsoraddress>Mater Mothers' Hospital
Raymond Terrace
South Brisbane
Queensland  4101</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Mater Mothers' Hospital</fundingname>
      <fundingaddress>Mater Health Services
Raymond Terrace
South Brisbane
Queensland  4101</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Mater Mothers' Hospital</sponsorname>
      <sponsoraddress>Raymond Terrace
South Brisbane
Queensland  4101</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project will assess the effect of progesterone therapy on pregnancy outcomes in women presenting with threatened miscarriage. It is hypothesised that progesterone supplementation for early threatened pregnancy increases the live birth rate.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mater Health Services Human Research Ethics Committee</ethicname>
      <ethicaddress>Mater Health Services
Raymond Terrace
South Brisbane
Queensland  4101</ethicaddress>
      <ethicapprovaldate>16/01/2012</ethicapprovaldate>
      <hrec>EC00332</hrec>
      <ethicsubmitdate>14/04/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Luke McLindon</name>
      <address>Mater Mothers' Hospital
Raymond Terrace
South Brisbane
Queensland  4101</address>
      <phone>61 7 3163 8111</phone>
      <fax />
      <email>lucas.mclindon@mater.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Chris Riley, RM</name>
      <address>Fertility Assessment and Research Clinic
Mater Mothers' Hospital
Raymond Terrace
South Brisbane
Queensland  4101</address>
      <phone>61 7 3163 8437</phone>
      <fax>61 7 3163 2137</fax>
      <email>naturalfertility@mater.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Luke McLindon</name>
      <address>Mater Mothers' Hospital
Raymond Terrace
South Brisbane
Queensland  4101</address>
      <phone>61 7 3163 8111</phone>
      <fax />
      <email>lucas.mclindon@mater.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>